WhiteLab Genomics Secured €23.2 Million Series B
The firm will use the capital to scale its ALFRED platform for AI-driven design of genomic medicine delivery vehicles.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you believe AI-driven technologies will significantly improve the effectiveness of medical treatments?
Founded in 2019, Paris-based WhiteLab Genomics has announced a €23.2 million ($26 million) Series B funding round. The investment will support the expansion of the company’s AI-driven drug design and in vivo validation efforts.
Why it matters
This capital injection accelerates the company's efforts to optimize genetic payloads and non-viral delivery technologies. It marks a transition for the firm toward scaling its experimental validation capabilities in international markets.
WhiteLab Genomics utilizes its proprietary ALFRED platform to design and optimize genetic payloads and delivery vehicles. The firm intends to expand this approach to include synthetic promoters and non-viral delivery systems.
The players
WhiteLab Genomics
A biotech firm using AI-driven platforms to design genomic medicines with operations in Paris, Boston, and Montreal.
AVP
A venture capital firm managing €2.5 billion in assets that led the recent funding round.
The details
The ALFRED platform leverages artificial intelligence to design, model, and optimize the functional components of genomic medicines. By automating the design of delivery vehicles—structures used to transport genetic material into cells—the company aims to shorten development cycles for novel therapies. This process is supplemented by in vivo testing to validate whether the AI-generated designs function effectively in a living biological system.
Timeline
2019: WhiteLab Genomics was founded.
October 6, 2026: The Series B funding round was announced.
The Tech Race
This raise follows the broader industry trend of prioritizing AI-assisted design over traditional, manual trial-and-error laboratory methods in genomic medicine. It highlights the competitive race to optimize non-viral delivery technologies and synthetic promoters.
While this news pertains to research-stage development, the firm plans to grow its presence in Boston and expand into Japan and South Korea. These regional expansions aim to shorten timelines for bringing new genomic medicine candidates to validation stages.
The takeaway
The firm is now focusing on broadening its proprietary platform to encompass synthetic promoters and non-viral delivery systems. Watch for updates on the company's planned expansion into the Japanese and South Korean markets in the coming quarters.
Further reading
Explore deeper insights into the sector in our Biotech section.
Live Poll
Do you believe AI-driven technologies will significantly improve the effectiveness of medical treatments?
